Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676650 | 0.97 | PDK1 (0.54) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL29695376 | 0.94 | PARP1 (0.50) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL30289174 | 0.92 | PARP1 (0.57) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL15606326 | 0.92 | PARP1 (0.57) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL3779343 | 0.92 | PDK1 (0.54) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL30289331 | 0.92 | PDK1 (0.54) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL4841744 | 0.91 | PDK1 (0.52) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6335353 | 0.91 | PARP1 (0.54) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL2820733 | 0.90 | PARP1 (0.55) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL20129643 | 0.90 | PARP1 (0.55) | PARP1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | EEF2K, VPS26B, VPS28 | PARP1 2867/4885PDK1 2151/4885PDK2 693/4885 |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | PARP1 2867/4885PDK1 2151/4885PDK2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.